Findlay Park Partners LLP Lowers Stock Position in STERIS plc $STE

Findlay Park Partners LLP trimmed its position in shares of STERIS plc (NYSE:STE) by 1.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 747,152 shares of the medical equipment provider’s stock after selling 13,500 shares during the period. STERIS makes up approximately 1.9% of Findlay Park Partners LLP’s holdings, making the stock its 21st biggest holding. Findlay Park Partners LLP’s holdings in STERIS were worth $184,875,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Steigerwald Gordon & Koch Inc. acquired a new stake in STERIS during the third quarter worth about $25,000. Spurstone Advisory Services LLC purchased a new stake in shares of STERIS during the 2nd quarter worth about $29,000. Cloud Capital Management LLC purchased a new stake in shares of STERIS during the 3rd quarter worth about $29,000. Geneos Wealth Management Inc. increased its position in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares in the last quarter. Finally, TruNorth Capital Management LLC purchased a new position in STERIS in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Price Performance

STE opened at $252.36 on Friday. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44. The firm has a market cap of $24.75 billion, a price-to-earnings ratio of 35.20 and a beta of 1.03. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The company has a fifty day simple moving average of $255.83 and a 200 day simple moving average of $251.68.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same period in the previous year, the company posted $2.32 earnings per share. The company’s quarterly revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities research analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s payout ratio is currently 35.15%.

Analysts Set New Price Targets

Several research firms have recently issued reports on STE. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.